Hypertension is an important risk factor for cardiovascular diseases. There is increasing evidence suggesting that inflammation is involved in the development of hypertension. Interleukin-6 (IL-6) is an important mediator of inflammatory response and the major regulator of hepatic production of acute phase proteins, such as fibrinogen and C-reactive protein (CRP), which have been associated with hypertension and cardiovascular diseases. Therefore, we studied the association of single nucleotide polymorphism (SNP) in the IL-6 gene (IL6) promoter with plasma levels of fibrinogen, CRP and hypertension. Five hundred and two Hong Kong Chinese subjects (282 normotensives and 220 hypertensives) were recruited. IL-6 gene promoter was examined for polymorphism and the study subjects were genotyped for any SNP identified. The IL6 À572C4G polymorphism (rs1800796) was found with a frequency of 0.23 for the minor G allele. Subjects with the À572G allele had significantly higher plasma fibrinogen (3.0670.57 vs 2.8370.60, P ¼ 0.002) and CRP (interquartile range 0.33-1.56 vs 0.12-0.93, P ¼ 0.003) levels than those without. The À572C4G polymorphism was found to be an independent predictor of fibrinogen and CRP levels after adjusting for confounding factors. Plasma concentrations of fibrinogen and CRP correlated with systolic blood pressure. However, the À572C/G genotype frequencies did not differ between hypertensive and normotensive subjects, and there was no association between À572C4G polymorphism and blood pressure. Our results provide evidence that there is a clear genetic influence of IL6 À572C4G polymorphism on plasma levels of fibrinogen and CRP, but this polymorphism does not lead to elevated blood pressure.
Introduction
Inflammation has a critical role in atherosclerosis and progression of cardiovascular diseases. 1 It is characterized by accumulation of inflammatory cells, production of cytokines and activation of acute phase response. Hypertension is considered as an important risk factor for stroke, myocardial infarction and cardiovascular disease, and affects 18% of the adult population in Hong Kong. 2 Accumulating information on vascular inflammation has indicated that inflammation may be involved in the initiation and development of hypertension, and hypertension has been suggested as a potentially pro-inflammatory condition. 3 As a key mediator of inflammatory response, interleukin-6 (IL-6) is considered to play important roles in atherogenesis [4] [5] [6] and is the principal regulator of production of acute phase proteins, including C-reactive protein (CRP), fibrinogen and plasminogen activator inhibitor-1 (PAI-1). [7] [8] [9] Fibrinogen is an important haemostatic and thrombotic risk factor 10 as well as an inflammatory marker, 11 and has been considered as an independent risk factor for cardiovascular and coronary heart diseases. [12] [13] [14] CRP, an acute phase protein and a marker of systemic inflammation, has also been found to be an independent cardiovascular risk factor. 13, 14 Elevated levels of CRP and fibrinogen are shown to have predictive value for future vascular events in apparently healthy subjects. [15] [16] [17] [18] Furthermore, circulating levels of fibrinogen and CRP have been found to be elevated in hypertension and associated with systolic blood pressure, [19] [20] [21] [22] and CRP levels have been demonstrated to be associated with an increased risk of developing hypertension, 23 suggesting that hypertension is in part an inflammatory disorder.
In healthy subjects, there is a large interindividual and intraindividual variability in plasma levels of fibrinogen and CRP, 24 which is likely to result from the interaction between genetic predisposition and environmental factors. 25 It has been clearly shown that fibrinogen and CRP levels are related to age and obesity, 22, 26 but several studies also demonstrate that a considerable part of the variation in concentrations of these inflammatory factors can be explained by genetic factors. 19, [27] [28] [29] Fibrinogen-b gene À455G4A polymorphism has found to be associated with increased fibrinogen level, 27 and it has been shown that genetic influence may attribute up to 34% of the level of fibrinogen. 28 Genetic polymorphisms in the CRP have been related to serum CRP and some of the haplotypes appear to be susceptibility markers for atherosclerosis. 19, 29 Given the role of IL-6 as a key mediator of acute phase reaction, single nucleotide polymorphisms (SNPs) in the IL-6 gene (IL6) have gained much attention, and a number of SNPs in the IL-6 gene promoter have been found to be related to the concentrations of acute phase proteins. [30] [31] [32] [33] [34] The IL-6 gene À174G4C polymorphism has been associated with PAI-l level in patients with or without hypertension, 30 and À174GG genotype has been associated with lower IL-6 levels after coronary artery bypass grafting (CABG) 31 and lower baseline fibrinogen levels in those subjects with CRP 40.33 mg/l. 32 The IL6 À174C4T polymorphism has been found to explain 14% of the baseline plasma CRP level. 33 The IL6 À572G4C polymorphism, which is rare in Caucasians, has also been associated with IL-6 levels in patients after CABG 31 and in those with acute coronary syndrome. 34 We, therefore, sought to study genetic variation in the promoter region of IL-6 gene in the Hong Kong Chinese Han population, and investigate their associations with baseline levels of fibrinogen and CRP and with blood pressure and hypertension.
Materials and methods

Subjects
A total of 502 unrelated Chinese of Han race living in Hong Kong were selected for the study. Of these, 282 were normotensive and 220 were hypertensive. Twenty subjects with history of ischaemic heart disease (IHD) or stroke were recruited for the screening for SNP in IL-6 gene promoter region. The study protocol has been approved by the Institutional Review Board, and written informed consent was obtained from all participants. The normotensive subjects and the subjects with history of IHD/stroke were recruited from a cohort of subjects previously randomly recruited from the general population. 35, 36 Hypertensive subjects were recruited from the Hypertension Clinic of a teaching hospital. Hypertension was defined as systolic blood pressure X140 mm Hg, or a diastolic blood pressure X90 mm Hg on at least three separate occasions. Patients on treatment previously diagnosed as hypertensive by the above criteria were also eligible. Patients with secondary hypertension (for example renal artery stenosis, coarctation, glomerulonephritis, pyelonephritis, phaeochromocytoma, Cushing's syndrome, Conn's syndrome) were excluded.
Subjects were studied in the morning after fasting overnight. Medical histories were obtained through a standard questionnaire, which included inquiry into use of antihypertensive medication and smoking status. Physical examination including measurement of height, weight, body mass index (BMI), waist circumference and percentage body fat were performed. Blood pressure was measured thrice at 5-min intervals. The mean of the second and third systolic and diastolic blood pressure readings were used for data analysis. Venous blood was taken after resting for at least 5 min for determination of fasting blood glucose, plasma insulin, lipid profile including high-density (HDL) and low-density lipoprotein (LDL)-cholesterol, triglyceride, fibrinogen and CRP. Insulin resistance was determined using the homeostasis model assessment of insulin resistance index (HOMA-IR), which is the product of the fasting plasma insulin in mIU/l and fasting plasma glucose in mmol/l divided by 22.5.
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SNP identification and genetic analysis Genomic DNA was extracted from the buffy coat using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. To screen for SNP, a 945-bp segment of the 5 0 -flanking region of IL-6 gene was amplified by polymerase chain reaction as described. 38 This was performed in 40 unrelated subjects (20 normotensive subjects and 20 subjects with a history of IHD or stroke), and any SNP present in the IL-6 gene promoter was identified by direct sequencing using ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). High-throughput genotyping of the SNP identified in the IL-6 gene promoter was then performed for all study subjects using the Sequenom MassARRAY system (Sequenom, San Diego, CA, USA) that utilizes Matrix Assisted Laser Desorption Ionization-Time Of Flight (MALDI-TOF) technology. Primers for SNP detection were designed using MassARRAY AssayDesign software (Sequenom, San Diego, CA, USA).
Fibrinogen and CRP assays
Plasma fibrinogen concentrations were measured in all study subjects using a photo-optical end point clot detection method on a Cobas Fibro instrument (Roche Diagnostics, Basle, Switzerland) with interassay coefficient of variation of 4.7%. Plasma CRP concentrations were determined in duplicate in 40% of the subjects (85 subjects that were randomly selected from the hypertensive group, and 117 sexand age-matched subjects that were selected from the normotensive group) by using high-sensitivity enzyme-linked immunosorbant assays (Anogen, Ontario, Canada) with intra-and inter-assay coefficients of variation of 8.5 and 17.2%, respectively. Plasma CRP levels 410 mg/l were considered to reflect clinical inflammation and the subjects were excluded from the data set.
Statistical analysis
Data were analysed using a statistical software program (SPSS for Windows, ver. 11.0, SPSS Inc., Chicago, IL, USA). Data are reported as mean7 standard deviation (s.d.). Plasma levels of CRP and insulin are given as median (interquartile range) and logarithmically transformed for analysis to reduce the skewness of their distribution. Comparisons of clinical characteristics in different groups or in groups with different genotypes were performed using unpaired Student's t-test and w 2 test for continuous and categorical variables, respectively. Genotype frequencies for each SNP were tested for Hardy-Weinberg equilibrium. Univariate analysis was used to evaluate the association between fibrinogen and CRP with other environmental or confounding factors. Stepwise multiple regression analyses were performed using fibrinogen and CRP as the dependent variables for all study subjects as well as for the subgroups of normotensive and hypertensive subjects to examine the independent predictor of fibrinogen and CRP levels. A two-tailed Po0.05 was considered statistically significant.
Results
General characteristics of the subjects The characteristics of 502 Chinese subjects, 282 normotensive and 220 hypertensive, are shown in Table 1 . There was no significant difference in the male:female ratio, but there were, as expected, differences in systolic and diastolic blood pressure between the hypertensive and normotensive group. Hypertensive subjects showed significantly higher age, BMI, waist circumference, cholesterol, triglyceride, fasting blood glucose, plasma insulin and HOMA-IR than the normotensive subjects. It can be noted that subjects with hypertension had significantly higher plasma fibrinogen levels (3.0870.59 vs 2.9270.60, P ¼ 0.004) than those without hypertension. CRP concentrations (measured in 202 subjects) were significantly higher in the hypertensives than the normotensives (P ¼ 0.021, Table 1 ). There were no significant differences in characteristics between the 220 hypertensive subjects and the subgroup of 85 hypertensive subjects who had a CRP measurement, or between the 282 normotensive subjects and the subgroup of 117 subjects who had a CRP measurement. In the hypertensive group, 100 subjects (45.5%) were on antihypertensive drug treatment.
Genotyping of SNP in IL-6 gene promoter Screening of genetic variant in the 940 bp fragment of IL-6 gene promoter (from À845 to exon 1) revealed the presence of a C4G polymorphism at position À572 relative to the transcription site (reference SNP ID: rs1800796) in eight of the 20 normotensive subjects and 10 of the 20 subjects with history of IHD/stroke, while no other SNP was detected. Genotyping of À572C/G polymorphism for the study subjects revealed a CC genotype in 303 subjects (61.0%), a CG in 163 (32.8%) and GG in 31 subjects (6.2%), whereas no specific signal was detected in five out of the 502 subjects studied. The genotypes IL6 À572C4G SNP and plasma levels of fibrinogen and CRP LYF Wong et al were in Hardy-Weinberg equilibrium (P ¼ 0.148, Table 2 ), but there was no significant difference in the frequencies of GG and CG genotype and the minor G allele between subjects with or without hypertension (P ¼ 0.781, Table 2 ). Owing to the small number of subjects who were homozygous for the À572C4G polymorphism, those with genotype GG were combined with those with genotype CG (IL6 À572G-carrier) in remaining analysis.
Relations of IL6 À572 C4G polymorphism with fibrinogen, CRP and blood pressure The characteristics of the subjects grouped by IL6 À572 genotypes are shown in Table 3 . There was no significant difference in age, gender, BMI, waist circumference, body fat content, lipid profiles and insulin resistance between the subjects with IL6 À572CC genotype and those carrying the À572G allele (Table 3) . However, the IL6 À572CG or GG genotypic group had significantly higher plasma fibrinogen and CRP levels than the homozygous CC genotypic group (Table 3 ). In the normotensive subjects, those carrying the CG or GG genotype had higher plasma fibrinogen (3.0670.57 vs 2.8370.60, P ¼ 0.002) and CRP (interquartile range 0.33-1.56 vs 0.12-0.93, P ¼ 0.003) levels than those carrying the CC genotype, whereas among the hypertensive subjects, there was no significant difference in fibrinogen (3.1470.59 vs 3.0470.59, P ¼ 0.190) and CRP (interquartile range 0.26-2.68 vs 0.21-2.24, P ¼ 0.491) levels between those carrying the CG or GG genotype and those carrying the CC genotype. As shown in Table 3 , there was no significant difference in blood pressure and frequency of hypertension between the two genotypic groups.
In Table 4 , the relationships of plasma concentrations of fibrinogen and CRP with other variables are shown. Plasma fibrinogen concentrations were related to age, percentage body fat and fasting blood glucose, and there was a positive correlation between plasma fibrinogen and systolic blood pressure. However, when the subjects were analysed according to normotensive and hypertensive subgroups, there was no significant relationship between fibrinogen levels and systolic blood pressure in the normotensive or hypertensive subgroups, whereas fibrinogen levels remained significantly related to age and body fat content in both subgroups. In the hypertensive subgroup, 100 sub- There was no significant relationship between plasma fibrinogen levels and blood pressures in those with or without antihypertensive drug treatment. Among the 202 subjects with CRP concentrations measured, concentrations of CRP were strongly correlated with fibrinogen levels and age. In addition, CRP levels were related to all measures of obesity, dyslipidemia and insulin resistance. CRP levels correlated with systolic blood pressure and the relationship was significant among the normotensive subjects (Table 4 ) and among the hypertensive subjects without antihypertensive drug treatment (r ¼ 0.350, P ¼ 0.027), but not in those hypertensive subjects with antihypertensive drug treatment. Multiple regression with fibrinogen as the dependent variable and the À572C4G polymorphism and potential confounding factors as independent variables showed that IL6 À572C4G polymorphism was an independent predictor of fibrinogen level (b ¼ 0.126, P ¼ 0.003) after adjustment for age and percentage body fat, but these variables explain only 12.0% of the variation in fibrinogen (Po0.001). The association of the À572C4G polymorphism with fibrinogen remained significant in the subgroup of normotensive subjects (b ¼ 0.164, P ¼ 0.004) but not in the hypertensive subgroup after controlling for all the confounding factors. Stepwise regression with CRP as dependent variable showed that the À572C4G polymorphism was an independent predictor of CRP level (b ¼ 0.198, P ¼ 0.002) after adjustment for age, waist circumference and HDLcholesterol, and these variables explain 24.4% of the variation in CRP (Po0.001) in the fully-adjusted model. Similar to fibrinogen, the association of the 
Discussion
We studied the genetic variation in the promoter region of IL-6, a factor upstream in the regulatory pathway of fibrinogen and CRP, and the most important finding in this study was the association of IL6 À572C4G polymorphism with elevated plasma levels of fibrinogen and CRP but not with any of the other variables that have been examined. Given the regulatory role of IL-6 in acute phase protein production, our results indicate that the À572C4G polymorphism may have functional significance and there is a clear genetic influence of such polymorphism in circulating levels of fibrinogen and CRP. IL6 À572C4G polymorphism is present in about 40% of our population, as shown in our study, but the À572G allele has a much higher frequency of 0.91 in African-Americans. 38 Several other SNPs in the IL-6 gene promoter, such as the À174G4C and À174C4T, which have been shown to be associated with CRP and PAI-1 levels were not detected in our sample population. These observa- tions indicate that there is a significant difference in the distribution of genetic polymorphisms in the IL-6 gene promoter among people of different races. As mentioned previously, CRP and fibrinogen have been found to be independent cardiovascular risk factors in prospective epidemiological studies. The C-allele of the IL6 À174G4C promoter polymorphism has been shown to be associated with CRP or IL-6 levels, but the relationship between À174G4C promoter polymorphism and risk of cardiovascular diseases is inconsistent in the different studies. [39] [40] On the other hand, two recent studies in Chinese Han population demonstrate that IL-6 gene À572G allele is associated with higher risk for coronary heart disease and myocardial infarction, and is related to higher expression of IL-6 from peripheral blood mononuclear cells. 41, 42 In addition, the À572CG genotype has also been shown to be predictive of IL-6 levels above 5 ng/l in patients with a subsequent cardiovascular event. 34 These findings support the notion that the IL6 À572C4G polymorphism has functional significance and suggest that the À572C4G polymorphism, by influencing CRP and fibrinogen levels, contributes to genetic risk for coronary heart disease in Chinese Han people.
In agreement with other reports, 22, 26 we found that the concentrations of fibrinogen and CRP were mainly related to age, body fat content and measures of obesity, while a small part of these variations could be explained by the À572C4G polymorphism. Several polymorphisms in the promoter region of fibrinogen and CRP genes, which are associated with fibrinogen or CRP levels, have also been shown to explain only a small part of the variation in concentrations of these inflammatory markers. 25, 43 These observations, together with our results, indicate that genetic predisposition may exert influence on baseline levels of CRP and fibrinogen but inflammatory triggers, such as obesity and increased body fat content, may play a more significant role in determining the concentrations of these inflammatory factors.
Although primary or essential hypertension has been considered as an independent risk factor of cardiovascular event, it is not a single entity but likely to result from the interaction between environmental factors and genetic predisposition of many polygenic quantitative traits acting in concert in different combinations in different individuals. 44 Obesity is one of the leading environmental factors for hypertension. 45 In our series, the hypertensive subjects had higher levels of CRP and fibrinogen than normotensive subjects, and the concentrations of fibrinogen and CRP were correlated with systolic blood pressure. Concentrations of CRP were strongly correlated with almost all of the obesity-related metabolic variables that could confound their associations with blood pressure. Our results raise the possibility that CRP may mediate the associations of these confounding factors with blood pressure and play a role in the development of hypertension. Given the statistically difference in CRP and fibrinogen levels between individuals classified by the IL6 À572C/G genotype, an association of À572C4G polymorphism with higher levels of systolic blood pressure and a higher prevalence of hypertension would be expected. However, this was not observed. Similar to our findings, Smith et al. demonstrate in their study of over 3500 subjects that there is no significant association between blood pressure and the 1059G4C polymorphism in the CRP gene, although the 1059G4C polymorphism is associated with elevated levels of CRP. 19 This is not surprising because the aetiology of hypertension is multifactorial. Nevertheless, CRP was an independent predictor of systolic blood pressure in our study, while controlling all the confounding factors. CRP exerts proinflammatory, proatherogenic and prothrombotic effects on endothelial cells, smooth muscle cells and monocyte-macrophages. [46] [47] [48] The evidence of a positive association between CRP and systolic blood pressure after adjustment for confounding factors support the observation that CRP levels are associated with the future development of hypertension, 23 and suggest that elevated levels of CRP may play a role in causing elevated blood pressure or reflect an underlying IL-6 response to a proinflammatory stimulus, which subsequently contributes to the development of hypertension. It seems that functional genetic variation in the IL-6 gene promoter, such as À572 C4G polymorphism, does not directly lead to elevated blood pressure, but it may modulate the response of IL-6 to obesity and inflammation, which would ultimately lead to the development of hypertension.
In conclusion, our study provides evidence for the genetic influence of IL6 À572C4G polymorphism in elevating plasma levels of fibrinogen and CRP in Hong Kong Chinese, which might have a functional significance in determining the circulating levels of acute-phase proteins in response to a proinflammatory stimulus, but the À572C4G polymorphism is not associated with hypertension in this population.
